Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

31
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
31
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

32
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
32

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia.

Atherosclerosis plus·2026
Same authorSame journal

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Journal of atherosclerosis and thrombosis·2026
Same author

Distribution of Lipoprotein(a) Levels Among Children with Elevated Low-Density Lipoprotein Cholesterol Identified Through Universal Pediatric Lipid Screening.

Journal of atherosclerosis and thrombosis·2026
Same author

Sex Differences in the Diagnosis and Treatment of Japanese Patients With Familial Hypercholesterolemia: A Retrospective Cohort Study.

Journal of lipid and atherosclerosis·2026
Same author

Current and Future Perspectives of LDL-C Lowering Therapies 2026.

Journal of atherosclerosis and thrombosis·2026
Same author

Severe HDL-C Deficiency Caused by Acquired LCAT Deficiency: A Case Report with Lipidomic Profiling and Anti-LCAT Autoantibody Detection.

Internal medicine (Tokyo, Japan)·2026

関連する実験動画

Updated: Sep 9, 2025

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans
04:40

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans

Published on: August 28, 2018

15.3K

痛風,尿酸,冠動脈疾患

Takuya Nakahashi1, Hayato Tada2, Kenji Sakata2

  • 1Division of Cardiology, Department of Internal Medicine, Takaoka City Hospital.

Journal of atherosclerosis and thrombosis
|August 31, 2025
PubMed
まとめ
この要約は機械生成です。

高血清尿酸 (高尿血症) は,心血管疾患と死亡率に関連しています. 尿酸の減少から恩恵を受ける患者を特定することは,残留心血管リスクの管理に極めて重要です.

キーワード:
冠動脈疾患二重エネルギーコンピュータトモグラフィー痛風ハイパーウリケミアモノナトリウムウラート結晶経皮冠動脈介入尿酸

さらに関連する動画

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.7K
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

2.1K

関連する実験動画

Last Updated: Sep 9, 2025

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans
04:40

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans

Published on: August 28, 2018

15.3K
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.7K
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

2.1K

科学分野:

  • 心臓病科
  • 生物化学
  • リウマトロジ

背景:

  • 血清尿酸 (UA) >7.0 mg/dLで定義される高尿血症は,痛風の前兆である.
  • 高血圧,糖尿病,脂質不全,死亡率の増加と関連しています.
  • UAの上昇は動脈硬化マーカーと内皮機能不全と相関しており,心血管疾患との病原性関連を示唆している.

研究 の 目的:

  • 冠動脈疾患 (CAD) に関する現在の理解をレビューする.
  • CAD患者の残留リスク因子としての高尿血症の管理のための将来の見通しについて議論する.

主な方法:

  • 高尿血症と心血管疾患に関する現在の証拠の文献レビュー.
  • 増加したUAと不良心血管事件の間の病原性の分析.
  • 痛風,単酸ナトリウム (MSU) の結晶の沈殿,および心血管への影響の検査.

主要な成果:

  • 心血管疾患 (CVD) の発生率と死亡率の増加と関連しています.
  • MSUの結晶は 関節だけでなく 冠動脈にも存在します
  • 尿酸を低下させる現在の治療は,高尿血症の心血管疾患を減少させるのに有効性が証明されていない.

結論:

  • ハイパーウリケミアは,CADの患者で重要な残留リスクを表します.
  • UAの減少から恩恵を受ける特定の患者のサブグループを特定することは非常に重要です.
  • CADにおける高尿血症の効果的な管理戦略を確立するには,さらなる研究が必要である.